- Conditions
- Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis, Avascular Necrosis, Post-traumatic Arthritis, Congenital Hip Dysplasia
- Interventions
- CATALYSTEM
- Device
- Lead sponsor
- Smith & Nephew, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 6
- States / cities
- San Francisco, California • Hamden, Connecticut • Orlando, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 10,347
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neurofibromatosis 1, Plexiform Neurofibroma
- Interventions
- Cabozantinib Oral Tablet, Selumetinib Oral Capsule
- Drug
- Lead sponsor
- Girish Dhall, MD
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Congenital Talipes Equinovarus
- Interventions
- Ankle Foot Orthosis (AFO)
- Device
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor, Tezacaftor/Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Oakland, California • San Diego, California + 30 more
- Conditions
- Achondroplasia, Dwarfism
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hyperandrogenism
- Interventions
- Blood sampling
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 8 Years to 15 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Friedreich Ataxia
- Interventions
- DT-216, Placebo
- Drug
- Lead sponsor
- Design Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Eatontown, New Jersey
- Conditions
- Epidermolysis Bullosa Simplex
- Interventions
- Filsuvez
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- GM1 Gangliosidoses, GM2 Gangliosidoses, Tay-Sachs Disease, Sandhoff Disease
- Interventions
- miglustat, Ketogenic Diet
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- Up to 204 Months
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cystic Fibrosis
- Interventions
- Orkambi
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Hepatic Porphyria
- Interventions
- Not listed
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 8
- States / cities
- San Francisco, California • Miami, Florida • Ann Arbor, Michigan + 5 more
- Conditions
- Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Congenital Heart Defect, Cardiopulmonary Bypass, Inflammatory Response, Low Cardiac Output Syndrome, Inflammation
- Interventions
- Single blood draw, Multiple blood draws
- Procedure
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia
- Interventions
- Enclitide Chloride, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Sacramento, California • Santa Ana, California + 17 more
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease, Light Chain Deposition Disease, Heavy Chain Deposition Disease, Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes, Smoldering Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Alzheimer's Disease in Down Syndrome
- Interventions
- Not listed
- Lead sponsor
- LuMind IDSC Foundation
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 46 participants
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- San Diego, California • Park Ridge, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Hereditary Angioedema
- Interventions
- Sebetralstat
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 2 Years to 11 Years
- U.S. locations
- 6
- States / cities
- San Diego, California • Evansville, Indiana • Wheaton, Maryland + 3 more
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Semaglutide (Rybelsus®), Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pompe Disease
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more
- Conditions
- Neurofibromatosis Type I, Plexiform Neurofibroma
- Interventions
- Nexavar (BAY 43-9006) (Sorafenib), Toxicity, Pharmacokinetics, Pharmacodynamics, Radiographic Evaluation, QOL assessment, Neuropsychological, Bony Toxicity
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Bethesda, Maryland
- Conditions
- HR+ HER2- Breast Cancer
- Interventions
- Serabelisib, Sapanisertib, Fulvestrant
- Drug
- Lead sponsor
- Faeth Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more
- Conditions
- SGA, Turner Syndrome, Noonan Syndrome, ISS
- Interventions
- Somapacitan
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Sacramento, California • Centennial, Colorado + 3 more
- Conditions
- End Stage Renal Disease, AV Fistula, Fistula, End Stage Kidney Disease
- Interventions
- Ellipsys Vascular Access Catheter
- Device
- Lead sponsor
- Medtronic Endovascular
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Tempe, Arizona • San Diego, California • Plano, Texas + 2 more
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
- Interventions
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Drug
- Lead sponsor
- T. John Winhusen, PhD
- Other
- Eligibility
- Not listed
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • Portland, Oregon + 6 more